

# Joseph P Nkolola

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2719883/joseph-p-nkolola-publications-by-year.pdf>

**Version:** 2023-06-07

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43  
papers

4,698  
citations

24  
h-index

49  
g-index

49  
ext. papers

6,291  
ext. citations

25  
avg, IF

5.04  
L-index

#	Paper	IF	Citations
43	A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques.. <i>Med</i> , <b>2022</b> ,	2.6	1
42	HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys.. <i>PLoS Pathogens</i> , <b>2022</b> , 18, e1010467	2.3	2
41	Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques.. <i>Npj Vaccines</i> , <b>2022</b> , 7, 53	3.5	0
40	Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. <i>Nature Medicine</i> , <b>2021</b> , 27, 1718-1724	15.4	5
39	Comparison of Subgenomic and Total RNA in SARS-CoV-2 Challenged Rhesus Macaques. <i>Journal of Virology</i> , <b>2021</b> ,	1.7	40
38	Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques. <i>Nature Communications</i> , <b>2021</b> , 12, 1474	5	7
37	Immunogenicity of the Ad26.COVS.S Vaccine for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 325, 1535-1544	7.4	139
36	Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays. <i>Journal of Virology</i> , <b>2021</b> ,	1.7	40
35	Protective efficacy of Ad26.COVS.S against SARS-CoV-2 B.1.351 in macaques. <i>Nature</i> , <b>2021</b> , 596, 423-427	16.4	22
34	Immunogenicity of Ad26.COVS.S vaccine against SARS-CoV-2 variants in humans. <i>Nature</i> , <b>2021</b> , 596, 268-272	16.2	122
33	Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 325, 2370-2380	7.4	120
32	Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 709994	2.94	0
31	Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. <i>Lancet Infectious Diseases</i> , <b>2020</b> , 20, 1061-1070	7.3	15
30	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. <i>Science</i> , <b>2020</b> , 369, 812-817	10	592
29	DNA vaccine protection against SARS-CoV-2 in rhesus macaques. <i>Science</i> , <b>2020</b> , 369, 806-811	10	748
28	Sustained maternal antibody and cellular immune responses in pregnant women infected with Zika virus and mother to infant transfer of Zika-specific antibodies. <i>American Journal of Reproductive Immunology</i> , <b>2020</b> , 84, e13288	1	4
27	Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. <i>Nature Medicine</i> , <b>2020</b> , 26, 498-501	15.4	17

26	Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22). <i>Lancet HIV,the</i> , <b>2020</b> , 7, e410-e421	2.6	11
25	Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. <i>Cell</i> , <b>2020</b> , 183, 185-196.e14	16.8	11
24	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , <b>2020</b> , 586, 583-588	16.4	550
23	Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics. <i>Nature Biomedical Engineering</i> , <b>2020</b> , 4, 1030-1043	6.8	21
22	Potently neutralizing and protective human antibodies against SARS-CoV-2. <i>Nature</i> , <b>2020</b> , 584, 443-449	16.4	609
21	Lack of therapeutic efficacy of an antibody to $\Delta$ n SIVmac251-infected rhesus macaques. <i>Science</i> , <b>2019</b> , 365, 1029-1033	10	21
20	Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. <i>Immunity</i> , <b>2019</b> , 50, 241-252.e6	7.3	96
19	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. <i>Cell Host and Microbe</i> , <b>2019</b> , 25, 59-72.e8	7.7	56
18	First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 218, 633-644	1.9	23
17	Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. <i>Journal of Virology</i> , <b>2018</b> , 92,	1.7	8
16	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). <i>Lancet, The</i> , <b>2018</b> , 392, 232-243	11.5	170
15	Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys. <i>Nature Medicine</i> , <b>2018</b> , 24, 721-723	15.4	35
14	First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1. <i>PLoS ONE</i> , <b>2018</b> , 13, e0205139	1.2	20
13	Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. <i>Nature</i> , <b>2018</b> , 563, 360-364	16.4	155
12	Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. <i>Immunity</i> , <b>2017</b> , 46, 1073-1088.e6	7.3	204
11	Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys. <i>Nature Communications</i> , <b>2017</b> , 8, 15740	5	10
10	Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	5.2	86
9	Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys. <i>Journal of Virology</i> , <b>2017</b> , 91,	1.7	27

8	Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. <i>Nature</i> , <b>2016</b> , 540, 284-287	16.4	183
7	SIV Infection-Mediated Changes in Gastrointestinal Bacterial Microbiome and Virome Are Associated with Immunodeficiency and Prevented by Vaccination. <i>Cell Host and Microbe</i> , <b>2016</b> , 19, 323-335	7.7	61
6	Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. <i>Science</i> , <b>2015</b> , 349, 320-4	10	236
5	A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component. <i>Journal of Virology</i> , <b>2015</b> , 89, 2507-19	1.7	33
4	Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer. <i>Journal of Virology</i> , <b>2014</b> , 88, 9538-52	1.7	28
3	Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer. <i>Vaccine</i> , <b>2014</b> , 32, 2109-16	1.7	23
2	Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies. <i>PLoS ONE</i> , <b>2014</b> , 9, e97229	1.2	50
1	Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. <i>Journal of Virology</i> , <b>2010</b> , 84, 3270-9	1.7	80